Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 3
R&D Momentum
27/100
Pipeline Velocity
6/100
Trial Completion Rate
60/100
Pipeline Concentration
33/100
Pipeline Freshness
100/100
Strategic Signals
Activity
Last 14 days
Study of RNS60 on Pain and Function After Hip Labral Repair
Pilot Study of RNS60 in Allergen-induced Bronchoconstriction
Study of RNS60 on Pain and Function After Knee Anterior Cruciate Ligament Surgery
Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)